| Literature DB >> 33181662 |
Ming Hu1,2, Caiwen Han1,2, Tiankang Guo1,2,3, Hongwei Tian1,2, Weipeng Zhan1,2, Jing Yang1,2, Wutang Jing1,2, Yuan Deng1,2, Xiaofei Li1,2, Shixun Ma1,2, Hui Cai1,2, Yuntao Ma1,2.
Abstract
The aim of this study is to investigate the feasibility and advantages of the da Vinci robotic system with the "3 + 2" mode (3 robotic arms and 2 assistants) in radical gastrectomy for gastric cancer.The clinical data of 65 patients who underwent da Vinci robotic gastrectomy with the "3 + 2" mode from July 2016 to October 2019 were grouped into an observation group. An additional 65 patients who underwent robotic gastrectomy under the classic mode during the same period were grouped into a control group. The short-term surgical outcomes were compared between 2 different groups.Compared with the control group, the observation group had a significantly shorter operative time (176.18 ± 15.49 vs 203.85 ± 12.77 minutes, P < .001) and lower operation costs ($2761.19 ± $191.91 vs $3690.91 ± $162.82; P < .001). No statistical differences in other outcomes were observed (P > .05).We show that robotic gastrectomy with "3 + 2" mode is a safe and beneficial surgical procedure in new robotic surgery institutions.Entities:
Mesh:
Year: 2020 PMID: 33181662 PMCID: PMC7668502 DOI: 10.1097/MD.0000000000022988
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1(A) R1, robotic first arm; R2, robotic second arm; A1, the first assistant; A2, the second assistant; C, the camera arm. (B) R1, robotic first arm; R2, robotic second arm; R3, robotic third arm; A1, the first assistant; C, the camera arm.
Figure 2(A) Dissected ligaments around the stomach. (B) Disconnect the duodenum by used endo-GIA.
Characteristics of patient between the 2 techniques.
| Patients characteristics | OG (n = 65) | CG (n = 65) | |
| Gender (M/F) | 39/26 | 46/19 | .197∗ |
| Age (yr) | 55.2 ± 7.2 | 57.2 ± 8.1 | .156† |
| BMI, median (IQR), kg/m2 | 23.8 [22.5–24.9] | 22.9 [22.4–23.7] | .134‡ |
| Comorbidity [n (%)] | 34 (52.3) | 29 (44.6) | .382∗ |
| Tumor maximum diameter, mean ± SD, mm | 45.4 ± 9.2 | 42.6 ± 9.3 | .125† |
| TNM stage | .395∗ | ||
| I | 12 (18.5) | 8 (12.3) | |
| II | 43 (66.2) | 50 (76.9) | |
| III | 10 (15.4) | 7 (10.8) |
Surgical outcomes, short-term postoperative courses and cost analysis.
| Clinical parameters | OG (n = 65) | CG (n = 65) | |
| Operative time (min) | 176.18 ± 15.49 | 203.85 ± 12.77 | <.001† |
| Estimated blood loss, median (IQR), mL | 90 [65–120] | 90 [60–120] | .321‡ |
| Conversion to laparotomy [n (%)] | 0 | 0 | N/A∗ |
| Postoperative hospital stay, median (IQR), d | 11 [10–12] | 12 [10.5–14] | .153‡ |
| Time to passage of flatus (d) | 2.8 ± 0.6 | 2.6 ± 0.5 | .192† |
| Lymph node yield, median (IQR) | 30 [28–32.5] | 29 [28–31] | .157‡ |
| Operation cost ($), mean (SD) | 2761.19 ± 191.91 | 3690.91 ± 162.82 | <.001† |
| Total of cost ($), mean (SD) | 10461.09 ± 401.86 | 11737.12 ± 910.43 | <.001† |
Multivariable linear regression model of factors associated with OT and OC.
| Operative time (OT) | Operation cost (OC) | |||||
| Factors | Coeff | 95% CI | Coeff | 95% CI | ||
| CG∗ | 27.41 | 2254 to 32.27 | <.01 | 833.35 | 753.16 to 913.54 | <.001 |
| Female† | −0.25 | −5.32 to 4.81 | .921 | 37.35 | −21.38 to 96.07 | .231 |
| Age (yr) | 0.54 | 0.23 to 0.84 | .001 | 8.14 | 4.43 to 11.85 | <.001 |
| BMI (kg/m2) | 1.34 | 0.09 to 2.58 | .035 | −1.86 | −16.53 to 12.79 | .802 |
| Largest tumor size (mm) | 0.34 | −0.22 to 0.29 | .793 | 2.17 | −0.8 to 5.55 | .151 |
| Lymph node yield | 0.52 | −0.42 to 1.46 | .271 | 6.36 | −4.59 to 17.31 | .252 |
| Estimated blood loss (mL) | 0.07 | −0.01 to 0.15 | .089 | -0.31 | −1.24 to 0.62 | .512 |
| Postoperative hospital stay (d) | – | – | – | – | – | – |
| Time to passage of flatus (d) | – | – | – | – | – | – |
| Operative time (min) | – | – | – | 3.49 | 1.41 to 5.57 | <.001 |
| Operation cost ($) | – | – | – | – | – | – |
Early and late complications (Clavien-Dindo grade ≥III).
| Complications | OG (n = 65) | CG (n = 65) | |
| Morbidity [n (%)] | 13 (20) | 11 (16.9) | .651 |
| Local complications [n (%)] | 12 (18.5) | 10 (15.4) | .645 |
| Anastomotic leakage [n (%)] | 1 (1.5) | 2 (3.1) | .50∗ |
| Pancreatic fistula [n (%)] | 1 (1.5) | 0 (0) | .50∗ |
| Intraperitoneal abscess [n (%)] | 2 (3.1) | 1 (1.5) | .50∗ |
| Bowel obstruction [n (%)] | 3 (4.6) | 1 (1.5) | .312∗ |
| Intraperitoneal bleeding [n (%)] | 1 (1.5) | 4 (6.2) | .183∗ |
| Anastomotic bleeding [n (%)] | 0 (0) | 2 (3.1) | .248∗ |
| Wound infection [n (%)] | 2 (3.1) | 1 (1.5) | .50∗ |
| Systemic complications [n (%)] | 2 (3.1) | 3 (4.6) | .50∗ |
| Pneumonia [n (%)] | 1 (1.5) | 2 (3.1) | .50∗ |
| Cardiac disease [n (%)] | 0 (0) | 1 (1.5) | .50∗ |
| Pulmonary embolism [n (%)] | 1 (1.5) | 0 (0) | .50∗ |
| Late complication (internal hernia) [n (%)] | 0 (0) | 0 (0) | NA |